Results 71 to 80 of about 15,937 (243)

Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial

Pediatrics and Neonatology
Background: Persistent Pulmonary Hypertension of the newborn (PPHN) is characterized by sustained elevated Pulmonary Artery Pressure (PAP). Drug resistance and the adverse effects of current therapeutic agents warrant investigation of other targeted ...
Mandana Kashaki, Arash Mohazzab, Mohammad Radgoudarzi, Arash Bordbar, Sama Dabbagh   +4 more
doaj   +1 more source

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

Canadian Respiratory Journal, 2018
Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH).
Su-Gang Gong, Lan Wang, Bigyan Pudasaini, Ping Yuan, Rong Jiang, Qin-Hua Zhao, Jing He, Rui Zhang, Wen-hui Wu, Jin-Ming Liu, Cai-cun Zhou   +10 more
doaj   +1 more source

In systemic sclerosis skin perfusion of hands is reduced and may predict the occurrence of new digital ulcers [PDF]

, 2017
Systemic sclerosis (SSc) patients are at high risk for the development of ischemic digital ulcers (DUs). The aim of this study was to assess in SSc patients a correlation between skin perfusion evaluated by LDPI and DUs and to evaluate the prognostic ...
Barbano, Biagio, Barilaro, Giuseppe, Gasperini, Maria Ludovica, Gigante, Antonietta, Marra, Alessandro Maria, Quarta, Silvia, Rosato, Edoardo   +6 more
core   +1 more source

A matter arising: When should inflammatory and autoimmune rheumatic diseases be considered ‘early’?

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Timely recognition of inflammatory and autoimmune rheumatic diseases (IARDs) is important to optimize the early diagnosis with tailored interventions and possible prevention of irreversible organ damage. This narrative review provides an update by summarizing the advances in identifying the early stages of rheumatoid arthritis, systemic sclerosis and ...
Elvis Hysa, Emanuele Gotelli, Carmen Pizzorni, Sabrina Paolino, Alberto Sulli, Vanessa Smith, Rosanna Campitiello, Maurizio Cutolo   +7 more
wiley   +1 more source

Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension [PDF]

Терапевтический архив, 2017
Aim. To provide a pharmacoeconomic estimate of macitentan versus bosentan in therapy for pulmonary arterial hypertension (PAH). Subject and methods. An analysis was carried out on the basis of a social perspective for patients, whose mean age was 50 ...
O M Moisseeva, A V Rudakova
doaj   +1 more source

Fibroblast‐driven MMP‐9/TIMP‐1 imbalance in bronchoalveolar lavage reflects fibrotic progression in interstitial lung disease

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Abstract Background Interstitial lung diseases (ILDs) are characterized by progressive fibrosis, in which extracellular matrix remodelling is regulated by matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). The MMP‐9/TIMP‐1 balance has been implicated in fibrogenesis, but its role in human ILD remains incompletely defined.
Maria Bertolotto, Daniela de Totero, Paolo Giannoni, Emanuela Barisione, Marco Grosso, Ennio Nano, Roberto Fiocca, Simona Pigozzi, Elisabetta Tedone, Luca Valle, Margherita Moriero, Daniela Verzola, Fabrizio Montecucco, Federico Carbone   +13 more
wiley   +1 more source

Preparation of orodispersible tablets of bosentan using xylitol and menthol as dissolution enhancers

Scientific Reports
Bosentan is a drug used to treat pulmonary hypertension via dual endothelial receptor antagonism. Bosentan has a restricted oral bioavailability, a problem that's mostly due to poor solubility and hepatic metabolism.
Rania Mohamed Sakr, Abdelaziz El Sayed Abdelaziz, Eman Ahmed Mazyed, Gamal Mohamed El Maghraby   +3 more
doaj   +1 more source

Cost effectiveness of first-line oral therapies for pulmonary arterial hypertension: A modelling study [PDF]

, 2016
Background: In recent years, a significant number of costly oral therapies have become available for the treatment of pulmonary arterial hypertension (PAH).
A Drabinski, A Macchia, A Roman, AH Briggs, AJ Peacock, AJ Sutton, AM Keogh, B He, DB Badesch, Doug Coyle, EJ Mills, G Savarese, GE D’Alonzo, GJ Taylor, HA Ghofrani, J Letarte, John Swiston, Julie Blouin, Karen Lee, Kathryn Coyle, Khai Tran, L Guillevin, Lisa Mielniczuk, M Humbert, MC Garin, MD McGoon, Mike Innes, Mohammed F. Jabr, N Galie, N Galie, N Galie, N Galie, O Sitbon, RL Benza, RL Fleurence, RN Channick, SJ Pocock, T Thenappan, TR Einarson, VV McLaughlin, Y Ling, YF Chen, YG Zheng   +42 more
core   +2 more sources

Microvascular Health as a Key Determinant of Organismal Aging

Advanced Science, Volume 12, Issue 47, December 18, 2025.
Abstract Aging is a complex, multifaceted process affecting all organ systems, with vascular aging playing a central role in organismal health decline. Beyond its role in circulation, the vascular system acts as a dynamic interface between tissues, influencing countless physiological functions such as tissue regeneration and repair, immune responses ...
Mattia Cenciarini, Andrea Uccelli, Francesca Mangili, Myriam Grunewald, Simone Bersini   +4 more
wiley   +1 more source

Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis [PDF]

, 2016
Background: Patients with pulmonary arterial hypertension (PAH) are managed according to evidence-based treatment guidelines. Methods and results: In this single-centre retrospective analysis, we examined outcomes of patients with PAH caused by ...
Condliffe, R., Griffiths, L., Heward, E., Mahadevan, V.S., Monfredi, O.   +4 more
core   +2 more sources